14 Search Results

q=Grants

Search Again


Shreeram Akilesh , MD, PhD

Email: shreeram@uw.edu

Phone: (206) 598-6408

Dr. Akilesh is presently applying next generation genomic tools and analyses to understand the development, structure and function of the kidney and its component cells in health and disease.

View Bio

Brittany Barber , MD, MSc, FRCSC

Email: bbarber1@uw.edu

Dr. Barber's clinical interests include head and neck cancer surgery, robotic surgery, and salivary and endocrine surgery. She has a special interest in reconstructive surgery for skin cancers. Her research interests include quality improvement in free flap reconstruction, peripheral nerve regeneration, cancer genomics, and HPV-related oropharyngeal cancer treatment.

View Bio

Susan Bullman , PhD

Email: sbullman@fredhutch.org

Phone: (206) 667-3449

The Bullman Lab focuses firstly on understanding the translational impact of the tumor microbiota in human cancers, and secondly on the delineation of specific mechanisms involved in the pathogenesis of microbe-associated human cancers. They combine molecular microbiology, computational biology, biochemistry, and genetics to understand host-microbial interactions within the tumor microenvironment. Through such efforts, her lab seeks to make discoveries that have both a scientific and clinical impact in the emerging area of bacterial-associated malignancies. Bacterial agents that have a role in cancer initiation or progression provide a viable route for prevention and treatment of these cancers.

View Bio

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Cole DeForest , PhD

Email: ProfCole@uw.edu

Phone: (206) 543-5961

The DeForest Group seeks to integrate the governing principles of rational design with fundamental concepts from material science, synthetic chemistry, and stem cell biology to conceptualize, create, and exploit next-generation materials to address a variety of health-related problems. They are currently interested in the development of new classes of user-programmable hydrogels whose biochemical and biophysical properties can be tuned in time and space over a variety of scales. Their work relies heavily on the utilization of cytocompatible bioorthogonal chemistries, several of which can be initiated with light and thereby confined to specific sub-volumes of a sample. By recapitulating the dynamic nature of the native tissue through 4D control of the material properties, these synthetic environments are utilized to probe and better understand basic cell function as well as to engineer complex heterogeneous tissue.

View Bio

Jeff Delrow , PhD

Email: jdelrow@fredhutch.org

Phone: (206) 667-2763

Dr. Delrow is the director of the bioinformatics resource at Fred Hutch. His primary role is to support researchers who need assistance with the analysis of genomics and proteomics data.

View Bio

Yawen Li , PhD

Email: liyw@uw.edu

Phone: (206) 616-8518

Dr. Li is interested in therapeutic and diagnostic radiopharmaceuticals, astatine labeling reagents for small molecule labeling, and developing chemical methods for separation of high specific activity medical radionuclides.

View Bio

Viswam Nair , MD, MS

Email: vnair@fredhutch.org

Phone: (206) 667-4971

Dr. Viswam Nair translates fundamental scientific discoveries into the clinic to improve the care of people with lung cancer. His research focuses on biomarkers, or telltale biological markers of health or disease. He studies how to best integrate molecular and imaging-based biomarkers into clinical practice to improve lung cancer detection and treatment.

View Bio

Kayode Ojo , PhD

Email: ojo67kk@uw.edu

Phone: (206) 543-0821

The research focus of the Ojo Lab is to develop novel, robust, safe and affordable antimicrobial agents that can withstand the threat of resistance while effectively treating debilitating parasitic diseases. They also have compounds in their drug library that could have an effect on breast, lung, melanoma and prostate cancer cells.

View Bio

Amy Paguirigan , PhD

Email: apaguiri@fredhutch.org

Phone: (206) 667-4352

The focus of my research has been the integration of emerging technologies to address clinically relevant questions in cancer biology. My focus is on the interface between clinical molecular biology, bioinformatics and biotechnology, in aiming to bridge the gaps to bring novel approaches in both the biotechnological and informatics realms to clinical molecular biology to study the role of clonal diversity in cancer therapy.

View Bio

Frank Schmitz , MD, PhD

Email: fschmitz@fredhutch.org

Dr. Schmitz is the Director of Translational and Molecular Medicine for the Chapuis Lab at Fred Hutch. He is working on a personalized anti-tumor vaccine approach, building off previous work in innate immunity and vaccine formulation during his postdocs.

View Bio

Takuma Uo , Ph.D.

Email: tuo@uw.edu

Phone: 206-897-5463

Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50. As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine, Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies. Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.

View Bio